<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>MANKIND on Financial Report Insights</title>
    <link>https://reports.muthu.co/tags/mankind/</link>
    <description>Recent content in MANKIND on Financial Report Insights</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 30 Jan 2025 15:12:00 +0000</lastBuildDate>
    <atom:link href="https://reports.muthu.co/tags/mankind/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Mankind Pharma Ltd - Jan 2025 Earnings Call Transcript Analysis</title>
      <link>https://reports.muthu.co/posts/mankind-pharma-ltd---jan-2025-earnings-call-transcript-analysis/</link>
      <pubDate>Thu, 30 Jan 2025 15:12:00 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/mankind-pharma-ltd---jan-2025-earnings-call-transcript-analysis/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;earnings-call-transcript-analysis-report&#34;&gt;&#xA;  Earnings Call Transcript Analysis Report&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#earnings-call-transcript-analysis-report&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;financial-performance&#34;&gt;&#xA;  Financial Performance&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#financial-performance&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;key-financial-metrics-q3-fy25&#34;&gt;&#xA;  Key Financial Metrics (Q3 FY25)&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#key-financial-metrics-q3-fy25&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Revenue:&lt;/strong&gt; INR 3,230 crores, up 24% YoY.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Organic growth: 11.2% YoY.&lt;/li&gt;&#xA;&lt;li&gt;Domestic organic growth: 8.4% YoY.&lt;/li&gt;&#xA;&lt;li&gt;Export organic growth: 43% YoY.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Adjusted EBITDA Margin:&lt;/strong&gt; 27.7%.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Reported EBITDA: INR 833 crores, up 36.4% YoY, margin of 25.8%.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Gross Margins:&lt;/strong&gt; Increased to 71% YoY from 68.3% in Q3 FY24.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;PAT:&lt;/strong&gt; Decreased by 16.4% to INR 385 crores.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Diluted EPS:&lt;/strong&gt; INR 9.4 per share.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Cash EPS:&lt;/strong&gt; INR 14.2 per share.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;R&amp;amp;D Expenses:&lt;/strong&gt; INR 71 crores (2.2% of sales).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Depreciation and Amortization:&lt;/strong&gt; INR 192 crores (includes INR 84 crores amortization from BSV assets).&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;key-financial-metrics-9m-fy25&#34;&gt;&#xA;  Key Financial Metrics (9M FY25)&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#key-financial-metrics-9m-fy25&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Revenue:&lt;/strong&gt; Increased by 17% YoY.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Adjusted EBITDA Margin:&lt;/strong&gt; 26.9%.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Reported EBITDA margin: 25.8%.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Organic Growth:&lt;/strong&gt; 12.3% YoY.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Domestic organic growth: 9.3% YoY.&lt;/li&gt;&#xA;&lt;li&gt;Export organic growth: 53% YoY.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Consolidated Effective Tax Rate:&lt;/strong&gt; 21.2%.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Cash Flow from Operations:&lt;/strong&gt; INR 1,599 crores (down 2.3% YoY).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Cash Flow to EBITDA Ratio:&lt;/strong&gt; 67.4%.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Capex Spends:&lt;/strong&gt; INR 344 crores (3.7% of total revenue).&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;guidance--forecasts&#34;&gt;&#xA;  Guidance &amp;amp; Forecasts&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#guidance--forecasts&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;R&amp;amp;D Expenses:&lt;/strong&gt; Stated guidance of 2% to 2.5% of sales.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Effective Tax Rate:&lt;/strong&gt; Guidance of 21% to 22%.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Capex:&lt;/strong&gt; Guidance of 4% to 5% of revenue.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Net Debt to Adjusted EBITDA:&lt;/strong&gt; Endeavor to achieve 2x by end of FY25.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Interest Cost (Next Quarter):&lt;/strong&gt; Expected to be in the range of INR 180-odd crores.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;areas-of-growth-or-decline&#34;&gt;&#xA;  Areas of Growth or Decline&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#areas-of-growth-or-decline&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Growth:&lt;/strong&gt; Overall revenue (driven by both organic and BSV acquisition), export business (organic growth of 43% in Q3, 53% in 9M), OTC business (30% YoY in Q3, 15% YoY in 9M), Chronic segment share (increased by 200 bps YoY to 37.6% ex-BSV).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Decline/Slowdown:&lt;/strong&gt; PAT (due to higher finance and amortization costs), organic domestic formulation growth (around 6.5-7% in Q3, impacted by acute segment softness and corrective measures).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Working Capital:&lt;/strong&gt; Net operating working capital days increased to 52 days from 45 days in the preceding quarter.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;strategic-initiatives--business-updates&#34;&gt;&#xA;  Strategic Initiatives &amp;amp; Business Updates&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#strategic-initiatives--business-updates&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;bsv-acquisition--integration&#34;&gt;&#xA;  BSV Acquisition &amp;amp; Integration&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#bsv-acquisition--integration&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Acquisition completed, BSV financials consolidated from October 23rd, 2024 (69 days in Q3).&lt;/li&gt;&#xA;&lt;li&gt;Integration is &amp;ldquo;on track.&amp;rdquo;&lt;/li&gt;&#xA;&lt;li&gt;Significant restructuring in the Rx business (TTK business of BSV), shifting to Mankind, field force optimization.&lt;/li&gt;&#xA;&lt;li&gt;Synergy benefits expected: INR 50-100 crores over 12-24 months.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;corrective-measures&#34;&gt;&#xA;  Corrective Measures&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#corrective-measures&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Delhi Pharma Divisions:&lt;/strong&gt; Undertaken to enhance field force productivity and efficiency. Nearing completion (80-90% done).&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Measures include addressing inefficiencies in primary/discounted sales, doctor coverage strategy, leadership changes.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;OTC Division:&lt;/strong&gt; Corrective measures completed, leading to robust growth.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;product-portfolio--rd&#34;&gt;&#xA;  Product Portfolio &amp;amp; R&amp;amp;D&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#product-portfolio--rd&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Expansion of DMF grade products: Over 215 (vs 150 in FY24), &amp;gt;90% in chronic segment.&lt;/li&gt;&#xA;&lt;li&gt;Partnership with Innovent Biologics: In-licensing of Sintilimab (PD-1 immunotherapy for cancer treatment).&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;financial-strategy&#34;&gt;&#xA;  Financial Strategy&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#financial-strategy&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Raised INR 10,000 crores (NCDs &amp;amp; CPs) for BSV acquisition.&lt;/li&gt;&#xA;&lt;li&gt;Raised INR 3,000 crores in equity, used to repay CPs.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;operational-changes&#34;&gt;&#xA;  Operational Changes&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#operational-changes&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;OTC business carved out into a wholly-owned subsidiary.&lt;/li&gt;&#xA;&lt;li&gt;Field force strength (Mankind): Increased from 16,043 (Mar 2024) to 16,570 (Dec 2024). Not cutting down, but replacing and optimizing.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;market--competitive-landscape&#34;&gt;&#xA;  Market &amp;amp; Competitive Landscape&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#market--competitive-landscape&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;market-share--positioning&#34;&gt;&#xA;  Market Share &amp;amp; Positioning&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#market-share--positioning&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;IPM market share (value): Increased by 40 bps to 4.8% (Dec &amp;lsquo;24) from 4.4% (Mar &amp;lsquo;24), &amp;ldquo;primarily driven by acquisition of BSV.&amp;rdquo;&lt;/li&gt;&#xA;&lt;li&gt;CVM Cardio Rank: Improved from 4th to 3rd in IPM.&lt;/li&gt;&#xA;&lt;li&gt;Aiming for leadership.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;industry-trends&#34;&gt;&#xA;  Industry Trends&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#industry-trends&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Chronic Segment Growth:&lt;/strong&gt; Continued outperformance in key chronic therapies. Mankind&amp;rsquo;s chronic share (ex-BSV) increased to 37.6% in Q3 FY25 from 35.6% in Q3 FY24.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Cancer Incidence:&lt;/strong&gt; Rising cancer cases in India, creating demand for innovative therapies like Sintilimab.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;competitive-actionsstatements&#34;&gt;&#xA;  Competitive Actions/Statements&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#competitive-actionsstatements&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Focus on &amp;ldquo;high entry barrier portfolios&amp;rdquo; and &amp;ldquo;specialty R&amp;amp;D tech platforms&amp;rdquo; through acquisitions like BSV.&lt;/li&gt;&#xA;&lt;li&gt;Corrective measures aimed at improving competitiveness and field force productivity against market.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;market-challengesopportunities&#34;&gt;&#xA;  Market Challenges/Opportunities&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#market-challengesopportunities&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Challenge:&lt;/strong&gt; Softer acute market for Mankind due to corrective measures and some regulatory impacts.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Opportunity:&lt;/strong&gt; Expanding into specialty/super-specialty segments (BSV), growing chronic market, robust OTC market potential.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;risk-factors--challenges&#34;&gt;&#xA;  Risk Factors &amp;amp; Challenges&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#risk-factors--challenges&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;corrective-actions-impact&#34;&gt;&#xA;  Corrective Actions Impact&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#corrective-actions-impact&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Temporary slowdown in growth, especially in the acute segment of the domestic pharma business.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;bsv-integration--restructuring&#34;&gt;&#xA;  BSV Integration &amp;amp; Restructuring&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#bsv-integration--restructuring&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Ongoing integration process for BSV.&lt;/li&gt;&#xA;&lt;li&gt;Restructuring of BSV&amp;rsquo;s Rx business leading to soft performance in that segment.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;regulatory-issues&#34;&gt;&#xA;  Regulatory Issues&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#regulatory-issues&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Impact on acute segment growth from regulatory tailwinds concerning emergency contraceptive pills, an FDC anti-infective, and a codeine preparation.&lt;/li&gt;&#xA;&lt;li&gt;DPCO matter affecting value growth in a gynaecology product.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;financial-metrics-pressure&#34;&gt;&#xA;  Financial Metrics Pressure&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#financial-metrics-pressure&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Higher finance costs and amortization from BSV acquisition impacting PAT.&lt;/li&gt;&#xA;&lt;li&gt;Increased working capital days.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;operational-constraints&#34;&gt;&#xA;  Operational Constraints&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#operational-constraints&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;New field force members (due to replacements during corrective actions) need time to build rapport and productivity.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;forward-looking-statements&#34;&gt;&#xA;  Forward-Looking Statements&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#forward-looking-statements&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;overall-outlook&#34;&gt;&#xA;  Overall Outlook&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#overall-outlook&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Confident in delivering sustainable long-term growth, supported by corrective actions and four growth engines.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;corrective-measures-completion&#34;&gt;&#xA;  Corrective Measures Completion&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#corrective-measures-completion&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Remaining 10-20% of corrective actions in Delhi pharma divisions to be completed in Q4 FY25.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;bsv-business&#34;&gt;&#xA;  BSV Business&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#bsv-business&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Priority is successful integration for long-term sustainable growth.&lt;/li&gt;&#xA;&lt;li&gt;Expected to grow 15%+ with higher export growth in the medium term.&lt;/li&gt;&#xA;&lt;li&gt;Margin improvement targeted: Starting at company average (26-28%), aiming for ~30% in 2-3 years, and &amp;ldquo;for sure in the next 5 years.&amp;rdquo;&lt;/li&gt;&#xA;&lt;li&gt;Rx business restructuring (TTK) to see improvements from Q4 onwards.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;financial-targets&#34;&gt;&#xA;  Financial Targets&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#financial-targets&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Net debt to adjusted EBITDA: Target of 2x by end of FY25.&lt;/li&gt;&#xA;&lt;li&gt;Interest cost next quarter: Around INR 180 crores.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;product-pipeline&#34;&gt;&#xA;  Product Pipeline&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#product-pipeline&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Planning to introduce a replacement (single molecule) for the anti-infective FDC affected by regulatory issues within a month.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;future-growth&#34;&gt;&#xA;  Future Growth&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#future-growth&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Expects growth to improve post-completion of corrective measures.&lt;/li&gt;&#xA;&lt;li&gt;Chronic PCPM expected to grow faster and eventually align with company average.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&#xA;&#xA;&#xA;&lt;div class=&#34;button-container&#34;&gt;    &#xA;    &lt;a href=&#34;https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09cab4ef-bf88-40b1-be1e-cabdff929690.pdf&#34; target=&#34;_blank&#34; class=&#34;report-button&#34;&gt;&#xA;      &lt;i class=&#34;fas fa-file-pdf&#34;&gt;&lt;/i&gt; Download Transcript&#xA;    &lt;/a&gt;&#xA;&lt;/div&gt;</description>
    </item>
    <item>
      <title>Mankind Pharma Ltd:Annual Report 2023-24 Analysis</title>
      <link>https://reports.muthu.co/posts/mankind-pharma-ltdannual-report-2023-24-analysis/</link>
      <pubDate>Thu, 18 Jul 2024 15:27:17 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/mankind-pharma-ltdannual-report-2023-24-analysis/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;mankind-pharma-ltd-a-comprehensive-overview&#34;&gt;&#xA;  Mankind Pharma Ltd.: A Comprehensive Overview&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#mankind-pharma-ltd-a-comprehensive-overview&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;about-the-company&#34;&gt;&#xA;  About the Company&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#about-the-company&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;p&gt;&lt;strong&gt;Year of Establishment and Founding History:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;Mankind Pharma was founded in 1986 by Mr. R.C. Juneja and Mr. Rajeev Juneja.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Headquarters Location and Global Presence:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;The company&amp;rsquo;s headquarters is located in New Delhi, India. Mankind Pharma has a presence in several international markets, including Southeast Asia, Africa, and CIS countries.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Company Vision and Mission:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Vision:&lt;/strong&gt; To become a leading global pharmaceutical company known for affordability, accessibility, and quality.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Mission:&lt;/strong&gt; To deliver high-quality, affordable healthcare solutions to people worldwide.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Key Milestones in Their Growth Journey:&lt;/strong&gt;&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
